Výsledky vyhledávání - "Kazutsune, Harada"

Etelcalcetide decreases the PTH–calcium setpoint without changing maximum and minimum PTH secretion in mice with primary hyperparathyroidism

Autor: Tomoaki Morioka, Yasuo Imanishi, Daichi Miyaoka, Atsuto Inoue, Noriyuki Hayashi, Masaaki Inaba, Masanori Emoto, Katsuhito Mori, Ikue Kobayashi, Tomoe Hirakawa, Tomomi Tateishi, Yuki Nagata, Kazutsune Harada

Publikováno v: Journal of Bone and Mineral Metabolism. 39:430-438

Etelcalcetide binds to the extracellular domain of the calcium-sensing receptor (CaSR), while cinacalcet binds to the 7-transmembrane domain of the CaSR; however, it is unknown, whether etelcalcetide has similar effects to cinacalcet on parathyroid h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e152efe3d07b93de065fe645630c5e45
https://doi.org/10.1007/s00774-020-01169-z

Zobrazit plný text záznamu

Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells

Autor: Hiroyuki Yamada, Masaaki Inaba, Yoshihiro Sugiura, Kazutsune Harada, Atsuto Inoue, Masanori Emoto, Tomoe Hirakawa, Mikiyasu Taguchi, Ikue Kobayashi, Noriyuki Hayashi, Yasuo Imanishi, Daichi Miyaoka, Aiko Fujioka

Publikováno v: Journal of Bone and Mineral Metabolism. 39:396-403

Etelcalcetide (Parsabiv®, AMG 416/ONO-5163) is a novel allosteric modulator for the calcium-sensing receptor approved for hemodialysis patients with secondary hyperparathyroidism of uremia. Etelcalcetide reduced parathyroid hormone levels in hemodia

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9cdf37fc17e8b599df06d1a13824c6b3
https://doi.org/10.1007/s00774-020-01158-2

Zobrazit plný text záznamu

Akademický článek

Characterization of the Trafficking Pathway of Cystic Fibrosis Transmembrane Conductance Regulator in Baby Hamster Kidney Cells

Autor: Tsukasa Okiyoneda, Kazutsune Harada, Kaori Yamahira, Ikuo Wada, Yasuaki Hashimoto, Keiko Ueno, Mary Ann Suico, Tsuyoshi Shuto, Hirofumi Kai

Publikováno v: Journal of Pharmacological Sciences, Vol 95, Iss 4, Pp 471-475 (2004)

To examine the unknown trafficking pathway of the cystic fibrosis transmembrane conductance regulator (CFTR) from the endoplasmic reticulum (ER), we utilized baby hamster kidney cells stably expressing CFTR fused with green fluorescent protein. CFTR

Externí odkaz: https://doaj.org/article/211c0fc9e7194ed6b2ee3afc1825e529

Zobrazit plný text záznamu

Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients

Autor: Kazutsune Harada, Yasushi Hirota, Aiko Fujioka, Hiroyuki Yamada, Masakazu Konno, Atsuto Inoue

Publikováno v: European Journal of Pharmacology. 842:139-145

Etelcalcetide hydrochloride (Parsabiv®, ONO-5163/AMG 416) is an allosteric modulator of the calcium (Ca)-sensing receptor that was originally produced by KAI Pharmaceuticals Inc. (now Amgen Inc.). It has recently been approved as the first intraveno

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::46cdac8aaf455c50f26834ba7294a8db
https://doi.org/10.1016/j.ejphar.2018.10.021

Zobrazit plný text záznamu

[The Discovery, Research and Development of Etelcalcetide Hydrochloride, the World 1st Intravenous Calcimimetics.]

Autor: Atsuto, Inoue, Kazutsune, Harada

Publikováno v: Clinical calcium. 27(4)

Etelcalcetide hydrochloride is the first intravenous calcimimetics agent for secondary hyperparathyroidism (SHPT). Etelcalcetide hydrochloride is to be administered through dialysis circuit by physician or medical staff upon completion of dialysis an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::15db0dc8a76d99413f7c80a9ee1a09d7
https://pubmed.ncbi.nlm.nih.gov/28336830

Zobrazit plný text záznamu

Role of calnexin in the ER quality control and productive folding of CFTR; differential effect of calnexin knockout on wild-type and ΔF508 CFTR

Autor: Akiko Niibori, Tsukasa Okiyoneda, Masahito Ikawa, Kazutsune Harada, Marek Duszyk, Mary Ann Suico, Marek Michalak, Tsuyoshi Shuto, Taijun Kohno, Hirofumi Kai, Ikuo Wada

Publikováno v: Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1783:1585-1594

Cystic fibrosis (CF) is caused by the mutation in CF transmembrane conductance regulator (CFTR), a cAMP-dependent Cl(-) channel at the plasma membrane of epithelium. The most common mutant, DeltaF508 CFTR, has competent Cl(-) channel function, but fa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba5bff9dcb91e54967cc29d38162022f
https://doi.org/10.1016/j.bbamcr.2008.04.002

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání